Anti-TrkB agonist antibodies binding to D5 domain of TrkB and methods of promoting neuronal survival in motor neuron injury, stroke or glaucoma
US10941203B2 · kind B2 · utility
1Cited by
23References
15Claims
0Family size
Inventors
Key dates
| Filing date | Mar 15, 2018 |
| Grant date | Mar 9, 2021 |
| Priority date | — |
| Expiry date | Mar 15, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is an isolated TrkB agonist antibody that binds to an epitope contained in one of the extracellular domains of TrkB and is capable of activating TrkB, wherein the extracellular domains comprises extracellular D1, D2, D3, D4, D5 domains and juxtamembrane domain of TrkB. Methods of using the TrkB agonist antibody in treating or reducing the risk of a TrkB associated conditions in a subject, wherein said condition is selected from cell differentiation, synaptic development, neural injury repairing and/or neurite branching.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.